| Kaitanni (cadonilimab) / Akesobio |
ChiCTR2300070963: Prospective, open cohort study of sulfatinib in combination with cadonilimab for first-line treatment of extensive-stage small-cell lung cancer |
|
|
| Not yet recruiting | 4 | 80 | | None ;None ;None ;None | The Second Hospital of Dalian Medical University; The Second Hospital of Dalian Medical University, self-finance | Small cell lung cancer | | | | |
ChiCTR2200065303: A single-arm, prospective, exploratory clinical study of fruquintinib plus candonilimab in advanced colorectal cancer |
|
|
| Not yet recruiting | 4 | 31 | | fruquintinib plus candonilimab | Nanjing Hospital of Traditional Chinese Medicine; Nanjing Hospital of Traditional Chinese Medicine, Self-financing | colorectal cancer | | | | |
ChiCTR2300071201: Exploratory clinical study of candonilimab plus bevacizumab in patients with relapsed diffuse midline glioma |
|
|
| Recruiting | 4 | 30 | | Cardonilizumab combined with bevacizumab was administered every 3 weeks until 1 year or disease progression or unacceptable toxicities, or withdrew consent. | Sanbo Brain Hospital Capital Medical University; Sanbo Brain Hospital Capital Medical University, Akeso Biopharma Co., Ltd. | diffuse midline glioma | | | | |
ChiCTR2300071681: A Phase II Clinical Study of Cadonilimab in Combination with Chemotherapy as First-Line Treatment for PD-L1 Negative Advanced Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 4 | 54 | | Cadonilimab + chemotherapy (chemotherapy regimen determined by the investigator) | Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital, Shanghai Pulmonary Hospital | Non-Small Cell Lung Cancer | | | | |
COMPASSIOn-15, NCT05008783: A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma |
|
|
| Active, not recruiting | 3 | 610 | RoW | AK104, Oxaliplatin, Capecitabine, Placebo | Akeso | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 08/24 | 04/25 | | |
AK109-301, NCT06341335: A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 3 | 506 | RoW | cadonilimab, AK104, pulocimab, AK109, paclitaxel, placebo | Akeso | Gastric and Gastroesophageal Junction Adenocarcinoma | 11/26 | 07/27 | | |
NCT06371157: A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 3 | 469 | RoW | AK104, Lenvatinib, TACE, Placebo for AK104, Placebo for Lenvatinib | Akeso | Hepatocellular Carcinoma | 10/25 | 05/26 | | |
NCT05587374: Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 418 | RoW | Cadonilimab, PD-1/CTLA-4 bi-specific antibody, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT | Sun Yat-sen University, Akeso Pharmaceuticals, Inc. | Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | 01/25 | 01/27 | | |
NCT05489289: A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection |
|
|
| Not yet recruiting | 3 | 405 | RoW | AK104, placebo | Akeso | Hepatocellular Carcinoma | 01/25 | 11/26 | | |
NCT04982237: A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer |
|
|
| Recruiting | 3 | 440 | RoW | AK104, paclitaxel, carboplatin, cisplatin, bevacizumab, Placebo | Akeso | Cervical Cancer | 04/25 | 12/25 | | |
NCT05990127: A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 642 | RoW | AK104, Tislelizumab, carboplatin, Pemetrexed, Paclitaxel | Akeso | Locally Advanced or Metastatic NSCLC | 08/25 | 11/26 | | |
AK104-305, NCT05235516: A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer |
|
|
| Recruiting | 3 | 636 | RoW | AK104, EBRT, BT, cisplatin, Placebo | Akeso | Locally Advanced Cervical Carcinoma | 05/26 | 05/29 | | |
NCT05941741: IC Plus Low-dose Radiation Plus Cadonilimab in LANPC |
|
|
| Recruiting | 3 | 380 | RoW | Intensity Modulated Radiation Therapy, IMRT, Chemotherapy, Induction chemotherapy, Concurrent chemotherapy, Gemcitabine, Cisplatin, Immune checkpoint inhibitor, Cadonilimab, AK104, PD-1/CTLA-4 inhibitor, Low-dose radiotherapy | Sun Yat-sen University | Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy | 12/26 | 12/29 | | |
NCT06241599: A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) |
|
|
| Recruiting | 2/3 | 300 | RoW | GP/PFLL+AK104, GP/PFLL+placebo | Sun Yat-sen University | Recurrent or Metastatic Nasopharyngeal Carcinoma | 02/26 | 02/29 | | |
NCT06221748: DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy |
|
|
| Recruiting | 2/3 | 90 | RoW | Disitamab Vedotin Injection, DV,RC48, Cadonilimab Injection, AK104, Cadonilimab Injection, Paclitaxel Injection | RemeGen Co., Ltd. | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 12/26 | 12/27 | | |
ChiCTR2300072956: A randomized, controlled, double-blind, multicenter phase II clinical study of PD-1/CTLA-4 dual antibody combined with chemoradiotherapy in the treatment of stage T1-2N2-3/T3-4N0-3M0 nasopharyngeal carcinoma |
|
|
| Not yet recruiting | 2/3 | 64 | | cadonilimab + induction chemotherapy + Concurrent chemoradiotherapy ;placebo + induction chemotherapy + Concurrent chemoradiotherapy | Sichuan Cancer Hospital; Sichuan Cancer Hospital, Sichuan Cancer Hospital Clinical Scientist Support Program Project | nasopharyngeal carcinoma | | | | |
NCT04728321: A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma |
|
|
| Completed | 2 | 32 | RoW | AK104 lenvatinib, AK104 | Akeso, Akeso Pharmaceuticals, Inc. | Hepatocellular Carcinoma | 08/22 | 08/23 | | |
| Not yet recruiting | 2 | 30 | NA | AK104+anlotinib | Chinese PLA General Hospital | Non-small Cell Lung Cancer | 09/22 | 09/23 | | |
ChiCTR2000035993: A phase II study of AK104 (binding kenetics to PD-1 and CTLA-4) in combination with anlotinib in patients with advanced NSCLC |
|
|
| Not yet recruiting | 2 | 30 | | AK104+anlotinib | Chinese PLA General Hospital; Chinese PLA General Hospital, Charity organization | Non-small cell lung cancer | | | | |
NCT04556253: AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 29 | NA | AK104 | Peking University | MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer | 10/22 | 10/23 | | |
NCT04868708: A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer |
|
|
| Completed | 2 | 50 | RoW | AK104, Bevacizumab, Paclitaxel, PTX, Cisplatin or Carboplatin, DDP,CBP | Akeso | Recurrent or Metastatic Cervical Cancer | 02/24 | 02/24 | | |
NCT05215067: A Phase II Trial of AK104 in Advanced Non-Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 40 | RoW | AK104, Docetaxel | Akeso | Advanced Non-small Cell Lung Cancer | 03/23 | 03/24 | | |
NCT05227651: AK104 in Neoadjuvant Treatment of Cervical Cancer |
|
|
| Not yet recruiting | 2 | 30 | RoW | AK104 | Akeso | Cervical Cancer | 03/23 | 06/23 | | |
NCT05886257: Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T |
|
|
| Withdrawn | 2 | | RoW | Candonilimab, Bevacizumab | Shi Ming | Hepatocellular Carcinoma | 03/23 | 03/23 | | |
| Recruiting | 2 | 60 | RoW | AK104, Lenvatinib, TACE | Akeso | Unresectable, Non-metastatic Hepatocellular Carcinoma | 04/23 | 06/25 | | |
NCT06383533: Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma |
|
|
| Recruiting | 2 | 28 | RoW | Disitamab Vedotin Plus Cadonilimab | Zhejiang Cancer Hospital | Bile Duct Adenocarcinoma Non-Resectable, HER2 Gene Mutation | 05/25 | 12/25 | | |
| Recruiting | 2 | 45 | RoW | HAIC-GEMOX+Cadonilimab+Regorafenib | Fudan University | Intrahepatic Cholangiocarcinoma | 05/25 | 05/26 | | |
NCT06341660: To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 30 | RoW | cadonilimab | Guangzhou Institute of Respiratory Disease | Non-small Cell Lung Cancer | 06/25 | 07/25 | | |
NCT06168786: Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC |
|
|
| Recruiting | 2 | 40 | RoW | Fruquintinib, Cadonilimab, SBRT | Huazhong University of Science and Technology | Colorectal Cancer | 02/26 | 02/27 | | |
| Recruiting | 2 | 54 | RoW | Cadonilimab, Cadonilimab group | Shanghai Pulmonary Hospital, Shanghai, China | NSCLC | 09/24 | 09/25 | | |
NCT06178601: A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma |
|
|
| Recruiting | 2 | 36 | RoW | RC48-ADC, AK104 | Shanxi Province Cancer Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Urothelial Carcinoma | 09/24 | 04/26 | | |
NCT06331650: A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 30 | RoW | cadonilimab | Guangzhou Institute of Respiratory Disease | Non-small Cell Lung Cancer | 08/25 | 10/25 | | |
NCT06209294: Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery |
|
|
| Recruiting | 2 | 30 | RoW | AK104, Carboplatin, Nab paclitaxel | Xiaohua Wu | Neoadjuvant Immunotherapy, Cervical Cancer, Fertility-sparing Surgery | 12/25 | 12/28 | | |
NCT06138496: Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC |
|
|
| Recruiting | 2 | 43 | RoW | Cadonilimab Combined With Lenvatinib | Sun Yat-sen University | Cadonilimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy | 08/25 | 12/25 | | |
NCT06455046: Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer |
|
|
| Recruiting | 2 | 37 | RoW | AK104, Cadonilimab, Recombinant Human Adenovirus 5 Injection, Recombinant Human Adenovirus Type 5 Injection | Fujian Cancer Hospital, Zhangzhou Municipal Hospital of Fujian Province | Cervical Cancer Recurrent | 10/25 | 10/25 | | |
NCT06406673: A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 70 | RoW | Cadonilimab+EC/ET+RT, Cadonilimab+vorolanib | Henan Cancer Hospital | Extensive Small Cell Lung Cancer | 08/24 | 12/24 | | |
NCT06154538: Cadonilimab + FOLFOX Versus FOLFOX in the Neoadjuvant Treatment of pMMR/MSS Locally Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 170 | RoW | Cadonilimab, 1, FOLFOX regimen | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Locally Advanced Colorectal Carcinoma | 11/26 | 11/28 | | |
ZF2023-252, NCT06277674: Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI |
|
|
| Recruiting | 2 | 20 | RoW | Cadonilimab plus Pemetrexed and Anlotinib, ICIs in combination with chemotherapy and antiangiogenic therapy | Guangzhou University of Traditional Chinese Medicine, Akeso Pharmaceuticals, Inc. | Non-small Cell Lung Cancer | 12/24 | 06/25 | | |
NCT05594914: AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 47 | NA | AK104 | The First Affiliated Hospital of University of South China | Esophageal Squamous Cell Carcinoma | 12/23 | 12/25 | | |
NCT05781958: Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC |
|
|
| Active, not recruiting | 2 | 64 | RoW | Cadonilimab+Gem/Cis | Shen Feng | Intrahepatic Cholangiocarcinoma | 12/23 | 12/24 | | |
| Recruiting | 2 | 40 | RoW | AK104 - Chemotherapy | Hunan Cancer Hospital | Ovarian Cancer | 12/23 | 01/26 | | |
CCGLC-011, NCT06187961: Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 36 | RoW | HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Lenvatinib plus cadonilimab, levima plus cadonilimab | Tongji Hospital, Geneplus-Beijing Co. Ltd. | Hepatocellular Carcinoma Non-resectable | 12/25 | 06/26 | | |
NCT06153368: Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC |
|
|
| Not yet recruiting | 2 | 30 | RoW | Cadonilimab+mFOLFIRINOX, Cadonilimab+Oxaliplatin+ Irinotecan+ Leucovorin+ 5-fluorouracil | The First Affiliated Hospital with Nanjing Medical University | Pancreatic Cancer | 11/24 | 11/25 | | |
| Not yet recruiting | 2 | 22 | RoW | Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody, Neoadjuvant therapy with Cadonilimab | LiuYing | Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy | 12/23 | 12/23 | | |
ChiCTR2200067057: Cadonilimab in combination with TPC chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patient who failed to prior immunotherapy: a prospective, open labeled phase II clinical trial |
|
|
| Completed | 2 | 25 | | cadonilimab in combination with TPC chemotherapy | Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center, NA | Nasopharyngeal Carcinoma | | | | |
NCT05760599: Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T |
|
|
| Recruiting | 2 | 30 | RoW | Candonilimab, Bevacizumab | Shi Ming | Hepatocellular Carcinoma | 01/24 | 07/24 | | |
NCT06218810: Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 53 | RoW | Cadonilimab + bevacizumab + FOLFOX | Fudan University | Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma, RAS Mutation, Cadonilimab | 12/25 | 12/26 | | |
NCT06196775: A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 36 | RoW | AK104+AK112 | Harbin Medical University | Hepatocellular Carcinoma | 01/26 | 01/27 | | |
NCT05926700: Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment |
|
|
| Recruiting | 2 | 27 | RoW | Candonilimab | Second Affiliated Hospital, School of Medicine, Zhejiang University | Soft Tissue Sarcoma | 08/24 | 01/25 | | |
NCT06202313: Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 128 | RoW | Cadonilimab, AK104, Eribulin | Shengjing Hospital | Triple Negative Breast Cancer | 12/25 | 12/28 | | |
NCT06251388: A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer |
|
|
| Recruiting | 2 | 50 | RoW | AK104, Cadonilimab Injection | West China Second University Hospital, Affiliated Hospital of North Sichuan Medical College, The Affiliated Hospital Of Southwest Medical University | Cervical Cancer | 05/25 | 10/26 | | |
NCT05377658: AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 43 | RoW | AK104, Cadonilimab, Albumin-Bound Paclitaxel, Carboplatin | Henan Cancer Hospital | Non-small Cell Lung Cancer | 12/24 | 12/27 | | |
NCT05947201: Neoadjuvant Treatment of Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 26 | RoW | Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil, rutine | Weijia Fang, MD, Akeso Pharmaceuticals, Inc. | The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC | 03/24 | 10/24 | | |
NCT05839470: Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer |
|
|
| Recruiting | 2 | 20 | RoW | cadonilimab, irinotecan, Oxaliplatin, leucovorin or levoleucovorin, 5-FU | Fujian Cancer Hospital | Colorectal Cancer | 03/24 | 03/25 | | |
NCT06310473: Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial |
|
|
| Not yet recruiting | 2 | 30 | RoW | Cadonilimab, AK104, Oxaliplatin, Capecitabine | Nanfang Hospital, Southern Medical University | Gastric Cancer, Esophagogastric Junction Cancer | 03/25 | 03/28 | | |
NCT06289751: Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer |
|
|
| Not yet recruiting | 2 | 50 | RoW | Cadonilimab, Cadonilimab Injection, Paclitaxel-albumin, Injectable paclitaxel (albumin bound), Cisplatin, Cisplatin injection, Extrafascial hysterectomy | Tongji Hospital, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Women Hospital, School of Medicine, Zhejiang University, Southwest Hospital, China, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sichuan Cancer Hospital and Research Institute, Qilu Hospital of Shandong University, Beijing Friendship Hospital, Tianjin Medical University, West China Second University Hospital, Xiangya Hospital of Central South University, Gansu Provincial Maternal and Child Health Care Hospital, Zhejiang Cancer Hospital, Shengjing Hospital | Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Radical Hysterectomy, Fertility Preservation | 03/26 | 01/31 | | |
NCT06467500: A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy |
|
|
| Recruiting | 2 | 48 | RoW | Cadonilimab (AK104) | Xin-Hua Xu | Non-small Cell Lung Cancer | 12/26 | 12/26 | | |
| Recruiting | 2 | 46 | RoW | Cadonilimab, AK104, Paclitaxel and cisplatin, taxol, DDP, intensity-modulated radiotherapy, IMRT | Sun Yat-sen University | Esophagus Cancer | 12/25 | 12/27 | | |
NCT06215651: Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Cadonilimab lenvatinib, AK104 | Peking Union Medical College Hospital | Cadonilimab and Lenvatinib | 01/25 | 01/27 | | |
NCT06280105: A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib |
|
|
| Not yet recruiting | 2 | 40 | RoW | Cadonilimab+regorafenib | Meng Chao Hepatobiliary Hospital of Fujian Medical University | Hepatocellular Carcinoma | 03/26 | 03/27 | | |
| Not yet recruiting | 2 | 80 | NA | AK104, Cadonilimab, Cisplatin, DDP, Paclitaxel, PTX | Chinese Academy of Medical Sciences, Akeso Pharmaceuticals, Inc. | Unresectable Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma | 04/24 | 10/24 | | |
NCT06202716: Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore |
|
|
| Not yet recruiting | 2 | 50 | RoW | Cadonilimab plus CapeOX chemotherapy | Nanfang Hospital, Southern Medical University | Gastric Cancer | 04/26 | 04/26 | | |
NCT06196697: AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer |
|
|
| Recruiting | 2 | 50 | RoW | Cadonilimab, AK104, Ivonescimab, AK112, XELOX, oxaliplatin and capecitabine, SOX, oxaliplatin and Tegafur | Harbin Medical University | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 01/27 | 03/27 | | |
NCT06405490: NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC |
|
|
| Recruiting | 2 | 30 | RoW | Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Nanoliposomal Irinotecan, Cadonilimab, Oxaliplatin, Capecitabine, First-Line, Advanced Cancer, Pancreatic Adenocarcinoma, Drug Use | 08/26 | 12/26 | | |
POINTS, NCT06356688: A Clinical Study on the Efficacy and Safety of Paclitaxel Polymer Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 30 | NA | paclitaxel polymer micelles and cisplatin combined with Cadonilimab | Sun Jing | Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | 04/25 | 06/25 | | |
NCT06349967: Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer |
|
|
| Not yet recruiting | 2 | 59 | NA | Nab-paclitaxel Combined With Cadonilimab (AK104) | West China Hospital | Gastric Cancer | 04/27 | 05/27 | | |
NCT06426797: Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 25 | NA | Cadonilimab plus anlotinib | Peking University People's Hospital, Akeso Pharmaceuticals, Inc. | Locally Advanced Esophageal Squamous Cell Carcinoma | 05/25 | 05/27 | | |
NCT06367075: A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma |
|
|
| Not yet recruiting | 2 | 53 | NA | Cadonilimab, AK104, Adriamycin, Doxorubicin | Wuhan Union Hospital, China, Sun Yat-sen University, Xiangya Hospital of Central South University, Yunnan Cancer Hospital, The Affiliated Hospital Of Guizhou Medical University, First Affiliated Hospital of Guangxi Medical University | Advanced Soft-tissue Sarcoma | 03/27 | 03/29 | | |
NCT06367088: Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer |
|
|
| Recruiting | 2 | 27 | RoW | Cadonilimab, physician's choice of chemotherapy | Wuhan Union Hospital, China | Triple-negative Breast Cancer, Cadonilimab | 04/26 | 04/27 | | |
NCT06406426: Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin |
|
|
| Recruiting | 2 | 40 | RoW | Cadonilimab and Fruquintinib Combined With Paclitaxel-albumin | Fudan University | Gastric / Gastroesophageal Junction Adenocarcinoma | 05/25 | 09/26 | | |
NCT06327698: Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure |
|
|
| Not yet recruiting | 2 | 30 | NA | Cadonilimab, AK104, anlotinib | Hunan Cancer Hospital | Melanoma | 05/26 | 05/27 | | |
AK104-IIT-C-M-0035, NCT06406634: Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Cadonilimab, AK104, Lenvatinib | Hunan Cancer Hospital | Hepatocellular Carcinoma | 04/26 | 04/27 | | |
NCT06438822: Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma |
|
|
| Not yet recruiting | 2 | 51 | NA | Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil | West China Hospital | Cholangiocarcinoma | 08/25 | 11/26 | | |
| Not yet recruiting | 2 | 30 | RoW | Cadonilimab+Lenvatinib | Shanghai Zhongshan Hospital, Sun Yat-sen University, Eastern Hepatobiliary Surgery Hospital | Hepatocellular Carcinoma | 05/26 | 05/27 | | |
NCT05687851: Study Of Candonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer |
|
|
| Recruiting | 2 | 33 | RoW | Candonilimab（AK104）, EBRT, BT | Chongqing University Cancer Hospital, Akeso Pharmaceuticals, Inc. | Locally Advanced Cervical Cancer | 06/24 | 12/26 | | |
NCT05833971: Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 43 | NA | cadonilimab+chemotherapy, AK104 | Guangzhou Institute of Respiratory Disease | Resectable Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | 06/24 | 06/26 | | |
CBC, NCT05812534: Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases |
|
|
| Not yet recruiting | 2 | 36 | NA | Cadonilimab | Second Affiliated Hospital of Nanchang University, Hunan Cancer Hospital, Fujian Cancer Hospital | Non Small Cell Lung Cancer, Brain Metastases | 06/24 | 06/25 | | |
Lung-AK104, NCT06448910: The Efficacy and Safety of Cadonilimab (AK104) as Induction and Consolidation Therapy for Locally Advanced/Unresectable NSCLC Patients Receiving Concurrent Chemoradiotherapy |
|
|
| Not yet recruiting | 2 | 41 | RoW | Cadonilimab (AK104), Concurrent Chemoradiotherapy | Fudan University | NSCLC, Locally Advanced Lung Carcinoma | 06/25 | 06/27 | | |
NCT06455254: Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM |
|
|
| Not yet recruiting | 2 | 44 | RoW | Candonilimab (AK104), Regorafenib | Jin-hong Chen | CRC | 12/25 | 06/26 | | |
AK112-IIT-C-W-0001, NCT06444009: A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 90 | NA | Ivonescimab combined with TP, ITP, Cadonilimab combined with TP, CTP, Penpulimab combined with TP, PTP | Lei Liu | Head and Neck Squamous Cell Carcinoma | 12/25 | 12/27 | | |
| Not yet recruiting | 2 | 59 | NA | Cadonilimab Combined with chemotherapy, AK104 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Akesobio | Pleural Mesothelioma | 06/27 | 06/29 | | |
NCT05980689: Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer |
|
|
| Recruiting | 2 | 33 | RoW | AK104, Cadonilimab, Capecitabine, Neoadjuvant Radiotherapy | Sun Yat-sen University, Akeso, Haplox Biotechnology Co., Ltd. | Locally Advanced Rectal Cancer | 06/24 | 01/25 | | |
NCT06472037: The Efficacy of Gemcitabine and Nab-palitaxe Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Patients With Locally Advanced Pancreatic Ductal Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 30 | RoW | Cadonilimab, Gemcitabine, Nab paclitaxel | Tianjin Medical University Cancer Institute and Hospital | Locally Advanced Pancreatic Ductal Adenocarcinoma | 05/25 | 07/25 | | |
NCT06427057: A Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors |
|
|
| Not yet recruiting | 2 | 40 | NA | Cadonilimab plus chemotherapy, Cadonilimab plus TKI | Tongji Hospital | Urinary System Tumor | 12/25 | 12/27 | | |
NCT05925413: Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 2 | 41 | RoW | Cadonilimab+TACE | Eastern Hepatobiliary Surgery Hospital | Hepatocellular Carcinoma | 07/24 | 07/25 | | |
NCT05256472: A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma |
|
|
| Recruiting | 2 | 70 | RoW | AK104, axitinib | Akeso | Renal Cell Carcinoma, First-line Treatment | 07/24 | 12/25 | | |
NCT05898256: Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2 | 20 | NA | Cadonilimab, AK104, Gemcitabine, Cisplatin | Guangxi Medical University | Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors | 07/24 | 07/26 | | |
NCT05974059: Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer |
|
|
| Not yet recruiting | 2 | 20 | RoW | Oxaliplatin, Capecitabine, Cadonilimab | Tianjin Medical University Cancer Institute and Hospital | Locally Advanced Unresectable Gastric Adenocarcinoma | 08/24 | 08/24 | | |
NCT05821361: HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 30 | RoW | HAIC+Cadonilimab+Bevacizumab | Tianjin Medical University Cancer Institute and Hospital | Unrescetable Hepatocellular Carcinoma | 08/24 | 08/25 | | |
NCT05896787: Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) |
|
|
| Not yet recruiting | 2 | 45 | RoW | AK104, nab-paclitaxel, carboplatin, Candonilimab，Preoperative Chemotherapy | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 08/24 | 08/26 | | |
NCT06074484: A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 36 | RoW | RC48-ADC, Disitamab Vedotin, AK104, Cadonilimab Injection | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Shanxi Province Cancer Hospital | Muscle Invasive Bladder Carcinoma | 08/24 | 08/25 | | |
NCT05932212: A Phase II Study of AK104 for Recurrent or Metastatic Vulvar Cancer |
|
|
| Not yet recruiting | 2 | 20 | RoW | AK104 | Akeso | Vulvar Cancer | 08/24 | 02/25 | | |
NCT05960955: Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 90 | RoW | Cadonilimab, AK117, Oxaliplatin, Tegafur-gimeracil-oteracil potassium, Docetaxel, 5-Fluorouracil | Akeso | Resectable Gastric or Gastroesophageal Junction Adenocarcinoma | 11/24 | 11/27 | | |
NCT05820906: Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Cadonilimab+Regorafenib+GC | Tianjin Medical University Cancer Institute and Hospital | Advanced Biliary Tract Cancer | 09/24 | 09/25 | | |
NCT06118645: Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance |
|
|
| Not yet recruiting | 2 | 40 | NA | cadonilimab combined +paclitaxel (albumin-bound) | China Medical University, China | Gastric Adenocarcinoma | 09/24 | 08/26 | | |
NCT06401005: SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC) |
|
|
| Not yet recruiting | 2 | 51 | NA | Cadonilimab (AK104) | Hubei Cancer Hospital | Breast Cancer | 08/26 | 09/27 | | |
NCT05815290: Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer |
|
|
| Recruiting | 2 | 50 | RoW | Cadonilimab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | dMMR Colorectal Cancer | 09/24 | 03/26 | | |
NCT06092645: Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma |
|
|
| Recruiting | 2 | 48 | RoW | surufatinib plus cadonilimab, surufatinib plus AK104 | Zhejiang Cancer Hospital | Bile Duct Adenocarcinoma | 10/24 | 10/25 | | |
NCT05817214: Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer |
|
|
| Recruiting | 2 | 35 | RoW | Cadonilimab, AK104, Anlotinib, AL001, Granulocyte-Macrophage Colony-Stimulating Factor | Zhongnan Hospital, Akeso Biopharma Co., Ltd. | Cervical Cancer | 11/25 | 02/27 | | |
ChiCTR2300071355: AK104 combined with regorafenib for third-line and above treatment of pMMR/MSS advanced colorectal cancer |
|
|
| Recruiting | 2 | 30 | | Cadonilimab in combination with regorafenib | National Cancer Center/Chinese Academy of Medical Sciences; National Cancer Center/Chinese Academy of Medical Sciences, No | pMMR/MSS advanced colorectal cancer | | | | |
